Jonathan Tobin, MD of Arix Bioscience discusses one of their portfolio companies, Artios Pharma, that's announced global strategic collaboration with Merck worth $7bn

Dec 03, 2020, 12:31 PM

Jonathan Tobin, Managing Director of Arix Bioscience #ARIX talks about one of their portfolio companies, Artios Pharma, that's announced global strategic collaboration with Merck that could be worth $ billions.

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.